Meningitis, Cryptococcal

• 

  Subject Areas on Research

  • A Sch9 protein kinase homologue controlling virulence independently of the cAMP pathway in Cryptococcus neoformans. 
  • AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial. 
  • Amphotericin B lipid complex in the treatment of experimental cryptococcal meningitis and disseminated candidosis. 
  • Assessing the virulence of Cryptococcus neoformans causing meningitis in HIV infected and uninfected patients in Vietnam. 
  • Brain inositol is a novel stimulator for promoting Cryptococcus penetration of the blood-brain barrier. 
  • Case 4: Weakness and Headaches in a 14-year-old Boy. 
  • Central nervous system cryptococcosis in solid organ transplant recipients: clinical relevance of abnormal neuroimaging findings. 
  • Cerebellar cryptococcoma in a patient with undiagnosed sarcoidosis: case report. 
  • Cryptococcal Antigen in Serum and Cerebrospinal Fluid for Detecting Cryptococcal Meningitis in Adults Living With Human Immunodeficiency Virus: Systematic Review and Meta-Analysis of Diagnostic Test Accuracy Studies. 
  • Cryptococcal meningitis in patients with glioma: a report of two cases. 
  • Cryptococcal ventricular-peritoneal shunt infection: clinical and epidemiological evaluation of two closely associated cases. 
  • Cryptococcosis diagnosis and treatment: What do we know now. 
  • Cryptococcosis. 
  • Cryptococcosis: a model for the understanding of infectious diseases. 
  • Cryptococcus deuterogattii VGIIa Infection Associated with Travel to the Pacific Northwest Outbreak Region in an Anti-Granulocyte-Macrophage Colony-Stimulating Factor Autoantibody-Positive Patient in the United States. 
  • Cryptococcus gattii genotype VGI infection in New England. 
  • Cryptococcus neoformans gene expression during experimental cryptococcal meningitis. 
  • Cryptococcus neoformans hyperfilamentous strain is hypervirulent in a murine model of cryptococcal meningoencephalitis. 
  • Efficacy of APX2039 in a Rabbit Model of Cryptococcal Meningitis. 
  • Efficacy of an abbreviated induction regimen of amphotericin B deoxycholate for cryptococcal meningoencephalitis: 3 days of therapy is equivalent to 14 days. 
  • Efficiently killing a sugar-coated yeast. 
  • Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis. 
  • Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans. 
  • Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance. 
  • Identifying the Patients Most Likely to Die from Cryptococcal Meningitis: Time to Move from Recognition to Intervention. 
  • In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus. 
  • In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. 
  • In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans. 
  • Inositol Metabolism Regulates Capsule Structure and Virulence in the Human Pathogen Cryptococcus neoformans. 
  • Karyotyping of Cryptococcus neoformans as an epidemiological tool. 
  • Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries. 
  • Microevolution of Serial Clinical Isolates of Cryptococcus neoformans var. grubii and C. gattii. 
  • Multilocus sequence typing of serially collected isolates of Cryptococcus from HIV-infected patients in South Africa. 
  • Neurological complications associated with HIV and AIDS: clinical implications for nursing. 
  • Novel Treatment of Cryptococcal Meningitis via Neurapheresis Therapy. 
  • Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis. 
  • Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients. 
  • Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints. 
  • Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. 
  • Prevalence, healthcare resource utilization and overall burden of fungal meningitis in the United States. 
  • Profiling a killer, the development of Cryptococcus neoformans. 
  • Pulmonary cryptococcosis in patients without HIV infection: factors associated with disseminated disease. 
  • Pulmonary cryptococcosis in solid organ transplant recipients: clinical relevance of serum cryptococcal antigen. 
  • RAS1 regulates filamentation, mating and growth at high temperature of Cryptococcus neoformans. 
  • Relationship of the glyoxylate pathway to the pathogenesis of Cryptococcus neoformans. 
  • Repeated therapeutic lumbar punctures in cryptococcal meningitis - necessity and/or opportunity? 
  • Sexual cycle of Cryptococcus neoformans var. grubii and virulence of congenic a and alpha isolates. 
  • Survival defects of Cryptococcus neoformans mutants exposed to human cerebrospinal fluid result in attenuated virulence in an experimental model of meningitis. 
  • Targeted gene replacement demonstrates that myristoyl-CoA: protein N-myristoyltransferase is essential for viability of Cryptococcus neoformans. 
  • The Cryptococcus neoformans transcriptome at the site of human meningitis. 
  • The STE12alpha homolog is required for haploid filamentation but largely dispensable for mating and virulence in Cryptococcus neoformans. 
  • The alpha-specific cell identity factor Sxi1alpha is not required for virulence of Cryptococcus neoformans. 
  • The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein. 
  • The war on cryptococcosis: A Review of the antifungal arsenal. 
  • Unusual pattern of enhancement in cryptococcal meningitis: in vivo findings with postmortem correlation. 
  • Very low levels of 25-hydroxyvitamin D are not associated with immunologic changes or clinical outcome in South African patients with HIV-associated cryptococcal meningitis.